Stockreport

Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors

Molecular Templates, Inc.  (MTEM) 
Last molecular templates, inc. earnings: 11/12 05:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.mtem.com/investor-relations
PDF AUSTIN, Texas, July 09, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company [Read more]